{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:28:29Z","timestamp":1790281709326,"version":"4.1.0"},"reference-count":101,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics and Practice"],"abstract":"<jats:p>Bullous pemphigoid (BP) is a rare autoimmune disease, primarily affecting elderly individuals, that significantly impacts the patient\u2019s quality of life. In contrast, psoriasis vulgaris (PV) is a common, chronic, immune-mediated skin condition recognized as a systemic T-cell-mediated disorder. We aim to present the case of a patient suffering from a dermatologic association of BP and PV, which unveiled hepatitis C viral infection as a potential trigger and led to complex therapeutic challenges. A literature review is also included, exploring previous cases of overlapping BP and PV, along with a discussion of the unique pathogenic mechanisms and an analysis of the available therapeutic options. The patient, a 53-year-old male with a seven-year history of PV, presented with tense bullae overlying the psoriatic papules and plaques, with a generalized distribution. The presence of hepatitis C infection was considered a potential trigger for the concurrent presentation of BP and PV. Recent GWASs have demonstrated a potential causal relationship between PV and the subsequent development of BP, suggesting shared genetic susceptibility and immune pathways. However, the exact mechanisms driving this transition remain incompletely understood. Our case is particularly relevant as it exemplifies how environmental triggers\u2014such as chronic hepatitis C infection\u2014together with chronic cutaneous inflammation may act as cofactors in this process, possibly through the \u2018epitope spreading\u2019 phenomenon. This case underlines the importance of identifying triggering factors in patients with overlapping autoimmune diseases and reinforces the need for future research to further elucidate the pathogenic link between genotype and phenotype, in order to improve personalized therapeutic strategies.<\/jats:p>","DOI":"10.3390\/clinpract15050091","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T06:47:15Z","timestamp":1746686835000},"page":"91","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bullous Pemphigoid Overlapping Psoriasis Vulgaris: A Rare Case Report and Literature Review"],"prefix":"10.3390","volume":"15","author":[{"given":"Maria-Alexandra","family":"Timofte","sequence":"first","affiliation":[{"name":"Department of Oncologic Dermatology, \u201cElias\u201d Emergency University Hospital, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4530-7965","authenticated-orcid":false,"given":"Constantin","family":"C\u0103runtu","sequence":"additional","affiliation":[{"name":"Department of Physiology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Dermatology, \u201cProf. N.C. Paulescu\u201d National Institute of Diabetes, Nutrition and Metabolic Diseases, 011233 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6652-4125","authenticated-orcid":false,"given":"Beatrice","family":"B\u0103l\u0103ceanu-Gur\u0103u","sequence":"additional","affiliation":[{"name":"Department of Oncologic Dermatology, \u201cElias\u201d Emergency University Hospital, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"M\u0103rg\u0103ritescu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Onco Team Diagnostic, 030138 Bucharest, Romania"},{"name":"Dermestetica, 011854 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u0103lin","family":"Giurc\u0103neanu","sequence":"additional","affiliation":[{"name":"Department of Oncologic Dermatology, \u201cElias\u201d Emergency University Hospital, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1436-0088","authenticated-orcid":false,"given":"Mara M\u0103d\u0103lina","family":"Mihai","sequence":"additional","affiliation":[{"name":"Department of Oncologic Dermatology, \u201cElias\u201d Emergency University Hospital, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Moro, F., Fania, L., Sinagra, J.L.M., Salemme, A., and Di Zenzo, G. (2020). Bullous Pemphigoid: Trigger and Predisposing Factors. Biomolecules, 10.","DOI":"10.3390\/biom10101432"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1590\/abd1806-4841.20199007","article-title":"Bullous pemphigoid","volume":"94","author":"Miyamoto","year":"2019","journal-title":"An. Bras. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Kridin, K., and Ludwig, R.J. (2018). The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations. Front. Med., 5.","DOI":"10.3389\/fmed.2018.00220"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00403-017-1736-1","article-title":"Prognostic factors for mortality in patients with bullous pemphigoid: A meta-analysis","volume":"309","author":"Liu","year":"2017","journal-title":"Arch. Dermatol. Res."},{"key":"ref_5","first-page":"5575111","article-title":"New-Onset Bullous Pemphigoid in a COVID-19 Patient","volume":"2021","author":"Olson","year":"2021","journal-title":"Case Rep. Dermatol. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/jocd.16042","article-title":"Clinicopathological characteristics of cutaneous complications following COVID-19 vaccination: A case series","volume":"23","author":"Diab","year":"2024","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Maronese, C.A., Caproni, M., Moltrasio, C., Genovese, G., Vezzoli, P., Sena, P., Previtali, G., Cozzani, E., Gasparini, G., and Parodi, A. (2022). Bullous Pemphigoid Associated with COVID-19 Vaccines: An Italian Multicentre Study. Front. Med., 9.","DOI":"10.3389\/fmed.2022.841506"},{"key":"ref_8","unstructured":"Baigrie, D., and Nookala, V. (2023). Bullous Pemphigoid. StatPearls, StatPearls Publishing."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0190-9622(89)70054-2","article-title":"Direct immunofluorescence in bullous pemphigoid: Effects of extent and location of lesions","volume":"20","author":"Weigand","year":"1989","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1067\/mjd.2001.117518","article-title":"Immunofluorescence in dermatology","volume":"45","author":"Mutasim","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00403-016-1631-1","article-title":"Evaluation of ELISA testing for BP180 and BP230 as a diagnostic modality for bullous pemphigoid: A clinical experience","volume":"308","author":"Keller","year":"2016","journal-title":"Arch. Dermatol. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0190-9622(96)90604-0","article-title":"Reactivity of autoantibodies from patients with defined subepidermal bullous diseases against 1 mol\/L salt-split skin. Specificity, sensitivity, and practical considerations","volume":"35","author":"Lazarova","year":"1996","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1600-0560.1999.tb01788.x","article-title":"Repeat direct immunofluorescence (DIF) test, using, 1 M NaCl treated skin, in the subepidermal autoimmune bullous diseases that contain IgG at the dermal epidermal junction","volume":"26","author":"Barnadas","year":"1999","journal-title":"J. Cutan. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Drenovska, K., Valeva, E., Shahid, M., and Vassileva, S. (2023). Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1148660"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Kridin, K., Ludwig, R.J., Schonmann, Y., Damiani, G., and Cohen, A.D. (2020). The Bidirectional Association Between Bullous Pemphigoid and Psoriasis: A Population-Based Cohort Study. Front. Med., 7.","DOI":"10.3389\/fmed.2020.00511"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1080\/09546634.2022.2089331","article-title":"Bullous pemphigoid induced by biologic drugs in psoriasis: A systematic review","volume":"33","author":"Steinhoff","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4103\/ijdvl.IJDVL_678_16","article-title":"Epidermolysis bullosa acquisita and anti-p200 pemphigoid as major subepidermal autoimmune bullous diseases diagnosed by floor binding on indirect immunofluorescence microscopy using human salt-split skin","volume":"83","author":"Goyal","year":"2017","journal-title":"Indian. J. Dermatol. Venereol. Leprol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.autrev.2019.06.007","article-title":"Epidermolysis bullosa acquisita: A comprehensive review","volume":"18","author":"Kridin","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_19","first-page":"e2020050","article-title":"Pemphigus Vulgaris and Bullous Pemphigoid: Update on Diagnosis and Treatment","volume":"10","author":"Casanova","year":"2020","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4103\/2229-5178.96707","article-title":"Coexistence of psoriasis with bullous pemphigoid","volume":"3","author":"Rao","year":"2012","journal-title":"Indian. Dermatol. Online J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0190-9622(85)70163-6","article-title":"Coexistence of psoriasis vulgaris and bullous diseases","volume":"13","author":"Grunwald","year":"1985","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1365-4632.2006.02861.x","article-title":"Concomitant psoriasis and bullous pemphigoid: Coincidence or pathogenic relationship?","volume":"45","author":"Wilczek","year":"2006","journal-title":"Int. J. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1523-1747.1998.00107.x","article-title":"Epitope Spreading: Lessons From Autoimmune Skin Diseases","volume":"110","author":"Chan","year":"1998","journal-title":"J. Investig. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.5826\/dpc.1501a4458","article-title":"Causal Relationship Between Psoriasis and Bullous Pemphigoid: A Mendelian Randomization Analysis","volume":"15","author":"Wang","year":"2025","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"H650","DOI":"10.1152\/ajpheart.2000.279.2.H650","article-title":"Adenosine A(2A) and A(2B) receptors in cultured human and porcine coronary artery endothelial cells","volume":"279","author":"Olanrewaju","year":"2000","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Ludwig, R.J., Vanhoorelbeke, K., Leypoldt, F., Kaya, Z., Bieber, K., McLachlan, S.M., Komorowski, L., Luo, J., Cabral-Marques, O., and Hammers, C.M. (2017). Mechanisms of Autoantibody-Induced Pathology. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.00603"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1046\/j.1365-2133.1996.d01-1072.x","article-title":"Acquired subepidermal bullous diseases associated with psoriasis: A clinical, immunopathological and immunogenetic study","volume":"135","author":"Kirtschig","year":"1996","journal-title":"Br. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Ciolfi, C., Sernicola, A., and Alaibac, M. (2024). HLA-Cw6 Polymorphism in Autoimmune Blistering Diseases. Biomolecules, 14.","DOI":"10.3390\/biom14091150"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjd.16083","article-title":"HLA-Cw6 and psoriasis","volume":"178","author":"Chen","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Maronese, C.A., Cassano, N., Genovese, G., Foti, C., Vena, G.A., and Marzano, A.V. (2022). The Intriguing Links between Psoriasis and Bullous Pemphigoid. J. Clin. Med., 12.","DOI":"10.3390\/jcm12010328"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1046\/j.1365-2133.1998.02169.x","article-title":"Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: Relationships with disease intensity","volume":"138","author":"Ameglio","year":"1998","journal-title":"Br. J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40257-023-00832-1","article-title":"Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update","volume":"25","author":"Karakioulaki","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Cozma, E.C., Avram, I., Voiculescu, V.M., Mihai, M.M., and G\u0103man, A.M. (2024). Correlations between Gut Microbiota and Hematological, Inflammatory, Biochemical and Oxidative Stress Parameters in Treatment-Na\u00efve Psoriasis Patients. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25126649"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.autrev.2011.04.003","article-title":"Autoimmune bullous diseases the spectrum of infectious agent antibodies and review of the literature","volume":"10","author":"Sagi","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"103286","DOI":"10.1016\/j.autrev.2023.103286","article-title":"COVID-19 and autoimmune bullous diseases: Lessons learned","volume":"22","author":"Kasperkiewicz","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"559","DOI":"10.4065\/70.6.559","article-title":"Chronic hepatitis C and skin diseases: A review","volume":"70","author":"Daoud","year":"1995","journal-title":"Mayo Clin. Proc."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/ajd.12899","article-title":"Association between bullous pemphigoid and psoriasis: Systematic review and meta-analysis of case-control studies","volume":"60","author":"Phan","year":"2019","journal-title":"Australas. J. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e15207","DOI":"10.1111\/dth.15207","article-title":"Guselkumab-associated bullous pemphigoid in a psoriasis patient: A case report and review of the literature","volume":"35","author":"Burlando","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"adv00224","DOI":"10.2340\/00015555-3457","article-title":"A Systematic Review of Drug-Induced Pemphigoid","volume":"100","author":"Verheyden","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/2013.jamadermatol.376","article-title":"The associations between bullous pemphigoid and drug use: A UK case-control study","volume":"149","author":"Chi","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1468-3083.2002.383_1.x","article-title":"Furosemide-induced bullous pemphigoid","volume":"16","author":"Baz","year":"2002","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_42","first-page":"360","article-title":"Bullous pemphigoid induced by hydrochlorothiazide therapy","volume":"13","author":"Warner","year":"2014","journal-title":"J. Drugs Dermatol."},{"key":"ref_43","first-page":"700","article-title":"Spironolactone-induced pemphigoid","volume":"124","author":"Grange","year":"1997","journal-title":"Ann. Dermatol. Venereol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/106002808902300115","article-title":"Bullous pemphigoid associated with captopril","volume":"23","author":"Mallet","year":"1989","journal-title":"DICP"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000250097","article-title":"Pemphigus provoked by D(-)penicillamine. An experimental approach using in vitro tissue cultures","volume":"164","author":"Ruocco","year":"1982","journal-title":"Dermatologica"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-4362.1991.tb03867.x","article-title":"Pemphigus and bullous pemphigoid due to drugs","volume":"30","author":"Ruocco","year":"1991","journal-title":"Int. J. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Popa, L.G., Giurcaneanu, C., Portelli, M.G., Mihai, M.M., Beiu, C., Orzan, O.A., Ion, A., and Anghel, T.H. (2024). Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice. Medicina, 60.","DOI":"10.3390\/medicina60030373"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/1346-8138.16832","article-title":"Simultaneous development of generalized pustular psoriasis and pemphigoid with multiple autoantibodies in a complete responder of pembrolizumab for lung cancer","volume":"50","author":"Kochi","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_49","first-page":"70","article-title":"Metastatic glucagonoma","volume":"41","author":"Dinc","year":"2009","journal-title":"Eurasian J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/qjmed\/95.12.834","article-title":"Glucagonoma syndrome presenting as psoriasis","volume":"95","author":"Beattie","year":"2002","journal-title":"QJM"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Martin, C.S., Parfeni, O.D., Popa, L.G., Mihai, M.M., Terzea, D., Herlea, V., Gherghe, M., Adam, R., Alnuaimi, O., and Calu, V. (2022). How Many Times Can One Go Back to the Drawing Board before the Accurate Diagnosis and Surgical Treatment of Glucagonoma?. Diagnostics, 12.","DOI":"10.3390\/diagnostics12010216"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1165\/rcmb.2008-0168OC","article-title":"The adenosine a2a receptor inhibits matrix-induced inflammation in a novel fashion","volume":"40","author":"Scheibner","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Noreen, A., Sultana, S., Sultana, T., Tabasum, S., Zia, K.M., Muzammil, Z., Jabeen, M., Lodhi, A.Z., and Sultana, S. (2020). Natural Polymers as Constituents of Bionanocomposites, Elsevier.","DOI":"10.1016\/B978-0-12-816751-9.00003-9"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1590\/abd1806-4841.20198032","article-title":"Bullous pemphigoid associated with psoriasis: A good response to methotrexate","volume":"94","author":"Vargas","year":"2019","journal-title":"An. Bras. Dermatol."},{"key":"ref_56","first-page":"676","article-title":"Bullous pemphigoid induced by adalimumab in a patient with psoriasis","volume":"159","author":"Trovato","year":"2024","journal-title":"Ital. J. Dermatol. Venerol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1189\/jlb.0908520","article-title":"Adenosine A2A receptors play an active role in mouse bone marrow-derived mesenchymal stem cell development","volume":"85","author":"Katebi","year":"2009","journal-title":"J. Leukoc. Biol."},{"key":"ref_58","first-page":"713","article-title":"Successful treatment with guselkumab of anti-p200 pemphigoid associated with plaque psoriasis","volume":"22","author":"Kitayama","year":"2024","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.abd.2023.07.017","article-title":"Multirefractory bullous pemphigoid, psoriasis and psoriatic arthritis successfully treated with guselkumab","volume":"99","year":"2024","journal-title":"An. Bras. Dermatol."},{"key":"ref_60","unstructured":"Bolognia, J., Schaffer, J.V., Duncan, K.O., Ko, C.J., and Elsevier, C. (2022). Dermatology Essentials, Elsevier. [2nd ed.]."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/1346-8138.16765","article-title":"Two cases with bullous pemphigoid relapsed after using interleukin-17A inhibitors for psoriasis: A paradoxical reaction","volume":"50","author":"Wang","year":"2003","journal-title":"J. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1111\/1346-8138.16189","article-title":"Incidental amelioration of bullous pemphigoid during ixekizumab treatment for psoriasis","volume":"49","author":"Lu","year":"2022","journal-title":"J. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s00403-025-04052-x","article-title":"A systematic review of the role of interleukin-17 inhibitors in bullous pemphigoid: Therapeutic and paradoxical effects","volume":"317","author":"Heidari","year":"2025","journal-title":"Arch. Dermatol. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2366535","DOI":"10.1080\/09546634.2024.2366535","article-title":"A case report of bullous pemphigoid following secukinumab therapy for a patient with psoriasis","volume":"35","author":"Wang","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Lugli, A.P., Caldarola, G., Falco, G.M., Montedoro, C., Mulas, C., and De Simone, C. (2024). Anti-IL-17 monoclonal antibodies and bullous pemphigoid: Treatment or causal agents? A case series and review of the literature. Drugs Context, 13.","DOI":"10.7573\/dic.2024-4-3"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1111\/1346-8138.17490","article-title":"Effective management of coexisting bullous pemphigoid and psoriasis with bimekizumab","volume":"52","author":"Okamura","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_67","first-page":"e60331","article-title":"Spesolimab in the Management of Generalized Pustular Psoriasis With Concurrent Bullous Pemphigoid and Psoriasis","volume":"16","author":"Teshima","year":"2024","journal-title":"Cureus"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Orzan, O.A., \u021aieranu, C.G., Olteanu, A.O., Doroban\u021bu, A.M., Cojocaru, A., Mihai, M.M., Popa, L.G., Gheorghiu, A.M., Giurc\u0103neanu, C., and Ion, A. (2023). An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15082171"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2302394","DOI":"10.1080\/09546634.2024.2302394","article-title":"Upadacitinib for the management of bullous pemphigoid coexisting with psoriasis vulgaris: A case report and literature review","volume":"35","author":"Su","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"110591","DOI":"10.1016\/j.intimp.2023.110591","article-title":"Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature","volume":"122","author":"Li","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jdcr.2022.12.006","article-title":"Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib","volume":"32","author":"Nash","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2246604","DOI":"10.1080\/09546634.2023.2246604","article-title":"Upadacitinib in nail psoriasis: A case report","volume":"34","author":"Wang","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jid.2019.11.005","article-title":"Recent Advances in Understanding Pemphigus and Bullous Pemphigoid","volume":"140","author":"Hammers","year":"2020","journal-title":"J. Invest. Dermatol."},{"key":"ref_74","first-page":"E046","article-title":"Coexistence of Psoriasis and Bullous Pemphigoid: Combination Treatment with Secukinumab and Methotrexate","volume":"7","author":"Yin","year":"2024","journal-title":"Int. J. Dermatol. Venereol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000435912","article-title":"Pemphigoid Diseases as a Sign of Active Psoriasis: A Case Report and Brief Review","volume":"231","author":"Iskandarli","year":"2015","journal-title":"Dermatology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40257-022-00719-7","article-title":"Management of Coexisting Bullous Pemphigoid and Psoriasis: A Review","volume":"23","author":"Hsieh","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","article-title":"European S3-guidelines on the systemic treatment of psoriasis vulgaris","volume":"23","author":"Pathirana","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/jdv.14114","article-title":"Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis","volume":"31","author":"Gisondi","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdv.15340","article-title":"French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults","volume":"33","author":"Amatore","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2014Part 1: Treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1746-1596-9-102","article-title":"Erythrodermic psoriasis with bullous pemphigoid: Combination treatment with methotrexate and compound glycyrrhizin","volume":"9","author":"Si","year":"2014","journal-title":"Diagn. Pathol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2147\/CCID.S374556","article-title":"Bullous Pemphigoid Associated with Erythrodermic Psoriasis: A Case Report","volume":"15","author":"Chen","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jdcr.2020.12.001","article-title":"A new eruption of bullous pemphigoid within psoriatic plaques following cyclosporine withdrawal","volume":"8","author":"Svigos","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3109\/15569527.2012.667030","article-title":"Coexistence of psoriasis and bullous pemphigoid: Remission with low-dose methotrexate","volume":"32","author":"Gunay","year":"2013","journal-title":"Cutan. Ocul. Toxicol."},{"key":"ref_85","first-page":"619","article-title":"Coexistence of psoriasis and pemphigoid\u2014Only a coincidence?","volume":"18","author":"Lazarczyk","year":"2006","journal-title":"Int. J. Mol. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4103\/idoj.IDOJ_416_18","article-title":"Epitope Spreading Phenomenon: A Case Report","volume":"10","author":"Krishnaswamy","year":"2019","journal-title":"Indian. Dermatol. Online J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0190-9622(08)80058-8","article-title":"Bullous pemphigoid and psoriasis: Treatment with cyclosporine","volume":"24","author":"Boixeda","year":"1991","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1751-7125.2008.07318.x","article-title":"Coexistent psoriasis and bullous pemphigoid responding to mycophenolate mofetil monotherapy","volume":"7","author":"Rallis","year":"2008","journal-title":"Skinmed"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1346-8138.2012.01659.x","article-title":"Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept","volume":"40","author":"Nin","year":"2013","journal-title":"J. Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2230.2007.02603.x","article-title":"A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy","volume":"33","author":"Saraceno","year":"2008","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1684\/ejd.2010.0970","article-title":"Coexisting bullous pemphigoid and psoriasis successfully treated with etanercept","volume":"20","author":"Cusano","year":"2010","journal-title":"Eur. J. Dermatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/j.jaad.2005.10.055","article-title":"Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept","volume":"54","author":"Yamauchi","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1111\/jdv.14002","article-title":"A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis","volume":"31","author":"Loget","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1111\/1346-8138.14760","article-title":"Secukinumab decreased circulating anti-BP180-NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid","volume":"46","author":"Kamata","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1111\/ajd.13803","article-title":"Successful secukinumab treatment of active bullous pemphigoid and chronic severe psoriasis: A case report","volume":"63","author":"Yun","year":"2022","journal-title":"Australas. J. Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1111\/1346-8138.16559","article-title":"Ixekizumab successfully treated refractory psoriasis concurrent bullous pemphigoid","volume":"50","author":"Xiao","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: The promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e15754","DOI":"10.1111\/dth.15754","article-title":"Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib","volume":"35","author":"Xiao","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamadermatol.2024.4688","article-title":"Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials","volume":"161","author":"Armstrong","year":"2025","journal-title":"JAMA Dermatol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Popescu, M.N., Beiu, C., Iliescu, M.G., Mihai, M.M., Popa, L.G., St\u0103nescu, A.M.A., and Berteanu, M. (2022). Botulinum Toxin Use for Modulating Neuroimmune Cutaneous Activity in Psoriasis. Medicina, 58.","DOI":"10.3390\/medicina58060813"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Ion, A., Doroban\u021bu, A.M., Popa, L.G., Mihai, M.M., and Orzan, O.A. (2022). Risks of Biologic Therapy and the Importance of Multidisciplinary Approach for an Accurate Management of Patients with Moderate-Severe Psoriasis and Concomitant Diseases. Biology, 11.","DOI":"10.3390\/biology11060808"}],"container-title":["Clinics and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2039-7283\/15\/5\/91\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:29:19Z","timestamp":1760030959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2039-7283\/15\/5\/91"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":101,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["clinpract15050091"],"URL":"https:\/\/doi.org\/10.3390\/clinpract15050091","relation":{},"ISSN":["2039-7283"],"issn-type":[{"value":"2039-7283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]}}}